secwatch.observer — SEC 8-K summary
======================================

Issuer:     RxSight, Inc. (RXST)
CIK:        0001111485
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0000950170-25-004478
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

RxSight reports preliminary Q4/FY2024 rev ~$40.2M/$139.9M, +41%/+57% YoY; guides 2025 rev $185-197M
--------------------------------------------------------------------------------

- Q4 2024 revenue ~$40.2M (+41% YoY); FY2024 ~$139.9M (+57% YoY).
- LAL procedure volume Q4 29,069 (+61% YoY); FY 98,055 (+79% YoY).
- LDD installed base 971 as of Dec 31 (+46% YoY); cash & investments $237.2M.
- 2025 revenue guidance $185M-$197M (32-41% growth); gross margin 71-73%.
- Preliminary results subject to audit; audited FY2024 & unaudited Q4 due Feb 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1111485/000095017025004478/0000950170-25-004478-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1111485/000095017025004478/rxst-20250112.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-004478

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer